Incyte Corporation Q3 2025 Financial Results

Incyte Corporation reported its third quarter 2025 financial results, showcasing significant growth across its product portfolio. Total revenues for the quarter were $1.37 billion, a 20% increase compared to the same period in 2024. This growth was primarily driven by a 19% increase in net product revenues, which totaled $1.15 billion. Key contributors to this growth included Jakafi® (ruxolitinib), which saw a 7% increase in net product revenue to $791 million, and Opzelura® (ruxolitinib) cream, which experienced a 35% increase to $188 million. The company also raised its full-year 2025 net product revenue guidance to $4.23 - $4.32 billion, reflecting higher demand for Jakafi and other hematology and oncology products. Incyte continues to focus on pipeline prioritization, with several key clinical trials and regulatory submissions expected in the coming months.